Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $27.9 million.

  • CytomX Therapeutics' Current Deferred Revenue fell 7846.3% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.9 million, marking a year-over-year decrease of 7846.3%. This contributed to the annual value of $94.1 million for FY2024, which is 5569.65% down from last year.
  • According to the latest figures from Q3 2025, CytomX Therapeutics' Current Deferred Revenue is $27.9 million, which was down 7846.3% from $32.3 million recorded in Q2 2025.
  • CytomX Therapeutics' Current Deferred Revenue's 5-year high stood at $301.3 million during Q4 2022, with a 5-year trough of $27.9 million in Q3 2025.
  • Moreover, its 5-year median value for Current Deferred Revenue was $183.4 million (2024), whereas its average is $167.3 million.
  • Per our database at Business Quant, CytomX Therapeutics' Current Deferred Revenue crashed by 8664.15% in 2021 and then soared by 57379.31% in 2022.
  • Over the past 5 years, CytomX Therapeutics' Current Deferred Revenue (Quarter) stood at $284.8 million in 2021, then grew by 5.82% to $301.3 million in 2022, then fell by 29.54% to $212.3 million in 2023, then tumbled by 55.7% to $94.1 million in 2024, then plummeted by 70.32% to $27.9 million in 2025.
  • Its Current Deferred Revenue was $27.9 million in Q3 2025, compared to $32.3 million in Q2 2025 and $49.4 million in Q1 2025.